135 related articles for article (PubMed ID: 32754328)
1. Efficacy and safety of nanosomal docetaxel lipid suspension based chemotherapy in gastric and gastroesophageal junction adenocarcinoma.
Subramanian S; Majumdar SKD; Biswas G; Joshi N; Bunger D; Khan MA; Ahmad I
Mol Clin Oncol; 2020 Sep; 13(3):14. PubMed ID: 32754328
[TBL] [Abstract][Full Text] [Related]
2. Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Breast Cancer: Results from a Multicenter Retrospective Study.
Subramanian S; Prasanna R; Biswas G; Das Majumdar SK; Joshi N; Bunger D; Khan MA; Ahmad I
Breast Cancer (Dove Med Press); 2020; 12():77-85. PubMed ID: 32547188
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Sarcoma: A Multicenter, Retrospective Study.
Narayanan P; Dattatreya PS; Prasanna R; Subramanian S; Jain K; Somanath NS; Joshi N; Bunger D; Khan MA; Chaturvedi A; Ahmad I
Sarcoma; 2019; 2019():3158590. PubMed ID: 31827370
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of nanosomal docetaxel lipid suspension-based chemotherapy in squamous cell carcinoma of the head and neck: A multicenter retrospective study.
Kumar Das Majumdar S; Subramanian S; Biswas G; Joshi N; Khan MA; Ahmad I
Oncol Lett; 2020 Dec; 20(6):344. PubMed ID: 33123255
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of nanosomal docetaxel lipid suspension based chemotherapy in metastatic ovarian carcinoma: A retrospective study.
Subramanian S; Samar A; Joshi N; Sejpal J; Khan MA; Ahmad I
Mol Clin Oncol; 2021 Aug; 15(2):162. PubMed ID: 34194740
[TBL] [Abstract][Full Text] [Related]
6. A Multicentric, Retrospective Efficacy and Safety Study of Nanosomal Docetaxel Lipid Suspension in Metastatic Castration-Resistant Prostate Cancer.
Samar A; Tiwari S; Subramanian S; Joshi N; Sejpal J; Khan MA; Ahmad I
Prostate Cancer; 2020; 2020():4242989. PubMed ID: 33381320
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension (NDLS) versus Conventional Docetaxel as Neoadjuvant and Adjuvant Therapy for Primary Operable Breast Cancer.
Badiginchala R; Dattatreya PS; Suresh AVS; Nirni SS; Andra VV; Bunger D; Chaturvedi A
Onco Targets Ther; 2023; 16():215-225. PubMed ID: 37033671
[TBL] [Abstract][Full Text] [Related]
8. Biweekly DoceAqualip in mCRPC patients beyond 20 cycles: A case series.
Tiwari S; Bisaria A; Kaur H; Joshi N; Sejpal J; Khan MA
J Oncol Pharm Pract; 2021 Dec; 27(8):2030-2034. PubMed ID: 33853469
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up.
Rosenberg AJ; Rademaker A; Hochster HS; Ryan T; Hensing T; Shankaran V; Baddi L; Mahalingam D; Mulcahy MF; Benson AB
Oncologist; 2019 Aug; 24(8):1039-e642. PubMed ID: 31138725
[TBL] [Abstract][Full Text] [Related]
10. Nanosomal Docetaxel Lipid Suspension: A Guide to Its Use in Cancer.
McKeage K
Clin Drug Investig; 2017 Apr; 37(4):405-410. PubMed ID: 28255844
[TBL] [Abstract][Full Text] [Related]
11. A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Lui A; Mulder K; Brezden-Masley C; Vickers M; Monzon J; Kennecke H; Goel R; Vos L; Ghosh S; Marginean H; Fields A; Maroun J; Spratlin J
Invest New Drugs; 2018 Aug; 36(4):674-682. PubMed ID: 29725881
[TBL] [Abstract][Full Text] [Related]
12. Nanosomal docetaxel lipid suspension based chemotherapy in a pregnant MBC patient - a case report.
Ramaswamy R; Joshi N; Khan MA; Siddhara S
Onco Targets Ther; 2019; 12():5679-5685. PubMed ID: 31406465
[TBL] [Abstract][Full Text] [Related]
13. A Multicenter Phase II Study of AMG 337 in Patients with
Van Cutsem E; Karaszewska B; Kang YK; Chung HC; Shankaran V; Siena S; Go NF; Yang H; Schupp M; Cunningham D
Clin Cancer Res; 2019 Apr; 25(8):2414-2423. PubMed ID: 30366938
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of a novel nanosomal docetaxel lipid suspension compared with taxotere in locally advanced or metastatic breast cancer patients.
Ahmad A; Sheikh S; Taran R; Srivastav SP; Prasad K; Rajappa SJ; Kumar V; Gopichand M; Paithankar M; Sharma M; Rane RC; Ahmad I
Clin Breast Cancer; 2014 Jun; 14(3):177-81. PubMed ID: 24287370
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
[TBL] [Abstract][Full Text] [Related]
16. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
Shah MA; Janjigian YY; Stoller R; Shibata S; Kemeny M; Krishnamurthi S; Su YB; Ocean A; Capanu M; Mehrotra B; Ritch P; Henderson C; Kelsen DP
J Clin Oncol; 2015 Nov; 33(33):3874-9. PubMed ID: 26438119
[TBL] [Abstract][Full Text] [Related]
17. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
Shah MA; Ramanathan RK; Ilson DH; Levnor A; D'Adamo D; O'Reilly E; Tse A; Trocola R; Schwartz L; Capanu M; Schwartz GK; Kelsen DP
J Clin Oncol; 2006 Nov; 24(33):5201-6. PubMed ID: 17114652
[TBL] [Abstract][Full Text] [Related]
18. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
[TBL] [Abstract][Full Text] [Related]
19. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
Fashoyin-Aje L; Donoghue M; Chen H; He K; Veeraraghavan J; Goldberg KB; Keegan P; McKee AE; Pazdur R
Oncologist; 2019 Jan; 24(1):103-109. PubMed ID: 30120163
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer.
Mondaca S; Margolis M; Sanchez-Vega F; Jonsson P; Riches JC; Ku GY; Hechtman JF; Tuvy Y; Berger MF; Shah MA; Kelsen DP; Ilson DH; Yu K; Goldberg Z; Epstein AS; Desai A; Chung V; Chou JF; Capanu M; Solit DB; Schultz N; Janjigian YY
Gastric Cancer; 2019 Mar; 22(2):355-362. PubMed ID: 30088161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
